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the building blocks 2-chloro pyridine-3-carboxylic acid [1] and 2-amino-6-methoxy-benzothiazole
[2]. All of the synthesized compounds have been conﬁrmed by elemental analyses, IR, 1H NMR
and 13C NMR spectral data. These newly synthesized compounds were screened for their antimicro-
bial activity. Variable and modest activity was observed against the investigated strains of bacteria
and fungi, however, compound 6h revealed signiﬁcant antibacterial activity against Escherichia coli.
Compounds 1, 2, 3, 5c, 5g and 5h, on the other hand, revealed potent antifungal activity against
Candida albicans compared to the reference drug greseofulvin.
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The number of life threatening infections caused by multidrug-
resistant Gram-positive pathogens has reached an alarming le-
vel in hospitals and the community. Infections caused by these
organisms create a serious challenge to the scientiﬁc commu-
nity and the need for an effective therapy has led to a search
for novel antibacterial agents.(N.B. Patel).
ity. All rights reserved. Peer-
d University.
lsevierPyridine and its derivatives are widely distributed in nature
and are well known to exhibit broad spectrum of biological activ-
ities such as antimicrobial (Gaonkar et al., 2007), anti-HIV (Ali
et al., 2007), anti-inﬂammatory (Hosni and Abdulla, 2008; Pav-
lova et al., 2001), analgesic (Hosni and Abdulla, 2008) and anti-
convulsant (Shaﬁee et al., 2004). Benzothiazole derivatives are
also associated with diverse biological activities viz. antiprolifer-
ative (Al-Soud et al., 2008), antimalarial (Hout et al., 2004), anti-
tumor (Mortimer et al., 2006; Racane et al., 2006; Akhtar et al.,
2008) and antimicrobial (Patel and Agravat, 2007).
Small ring heterocycles containing nitrogen, sulfur and
oxygen gained great importance since a long time due to their
important medicinal properties. Particularly, 4-thiazolidinon-
es have been shown to have various important biological
activities such as anti-inﬂammatory (Geronikaki et al.,
2008), antitubercular (Parekh et al., 2004), antimicrobial
(Lokhandwala and Desai, 2008), anticonvulsant (Ulusoy
et al., 1998), antiviral (Terzioglu et al., 2006) and anti-HIV
(Balzarini et al., 2009; Ravichandran et al., 2008; Rawal
et al., 2007a,b).
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idine, benzothiazole and Schiff bases/4-thiazolidinone moieties
would result in compounds of interesting biological activities.
In view of these ﬁndings, we have attempted to incorporate
all these three biologically active components together to give
a conﬁned structure like the titled compounds for evaluating
its antimicrobial activity.
We have already reported some of our work on the synthesis,
transformations and biological properties of various 4-thiazo-
lidinones (Patel and Patel, 2007; Patel andRathod, 2007). These
compounds were screened for their antibacterial and antifungal
activities and it was found that some of them have moderate to
good biological properties. The biological signiﬁcance of this
class of compounds impelled us to continue working on the syn-
thesis of new 4-thiazolidinone derivatives. In this study, we have
reported the synthesis of some new 4-thiazolidinone derivatives
derived from Schiff bases of pyridine derivatives.
2. Materials and methods
2.1. General
Laboratory chemicals were supplied by Rankem India Ltd.,
and Fischer Scientiﬁc Ltd. Melting points of the synthesized
compounds were determined in open-glass capillaries on Stu-
art-SMP10 melting point apparatus and were uncorrected.
The purity of the compounds was checked by thin layer chro-
matography (TLC). Silica gel plates kiesel gel 0.25 mm, 60G
F254, precoated sheets obtained from Merck, Darmstadt (Ger-
many) were used for TLC. Developing solvent system of tolu-
ene:ethyl acetate (3:1) was used and the spots were visualised
by iodine vapours/ultraviolet light as visualizing agent.
IR spectra (KBr disc) were recorded on Perkin–Elmer-838
FT-IR spectrometer, using KBr pellets in the range of 4000–
400 cm1.
1H NMR and 13C NMR spectra were scanned on Bruker
Avance II 400 spectrometer at 400 MHz and 100 MHz for
1H NMR and 13C NMR respectively, Chemical shifts are ex-
pressed in d (ppm) relative to TMS as an internal standard
using DMSO-d6 as solvent.
Elemental analyses of the newly synthesized compounds
were performed on Carlo Erba 1108 analyzer. Elemental anal-
yses of all the compounds were in agreement with the calcu-
lated values.
Antimicrobial activity was performed at Micro Care Labo-
ratory, Suart according to the protocol mentioned in the Sec-
tion 2.3 antimicrobial screening using broth dilution method
(Rattan, 2005).
2.2. Chemistry
The building blocks 2-amino-6-methoxybenzothiazole [2] and
2-[N-(6-methoxybenzothiazolyl)amino] pyridine-3-carboxylic
acid [3] were prepared according to the reported procedures
(Patel and Agravat, 2007).
2.2.1. Preparation of building block 2-[N-(6-methoxy-
benzothiazolyl)amino] pyridine-3-carboxo hydrazide [4]
2-[N-(6-methoxybenzothiazolyl)amino] pyridine-3-carboxylic
acid 3 (0.01 mol) in SOCl2 (7.0 ml) was reﬂuxed on water bath
until the reaction was completed. The mixture was protectedfrom humidity with CaCl2 guard tube. The excess of SOCl2
was removed by vacuum distillation. The solid material 2-[N-
(6-methoxybenzothiazolyl)amino] pyridine-3-carbonyl chlo-
ride was obtained, which was directly used in the next step.
Hydrazine hydrate (0.02 mol, 80%) in chloroform (5 mL)
was added dropwise in a mixture of acid chloride (0.01 mol)
in chloroform (10 mL) and triethylamine (2–3 drops) while
stirring at 0–5 C for half an hour and the stirring was contin-
ued at room temperature for 3–4 h. The solvent was evapo-
rated and the product obtained was collected, dried and
recrystallized from methanol. m.p. – 245–247 C, yield, 68%;
IR (KBr) cm1: 3339 (–NH str.), 1648 (CONH, amide-I),
1542 (amide-II), 1224 (amide-III), 1469 (C–N, C–C ring str.),
1337 (C–N str.), 1025, 1205 (C–O–C sym., asym.). 1H NMR
(DMSO-d6) d (ppm): 8.30–6.90 (6H, m, pyridine and aro-
matic), 9.35 (1H, s, –NH–), 8.95 (1H, s, –CONH–), 4.10
(2H, s, –NH2), 3.88 (3H, s, OCH3).
2.2.2. General method for preparation of hydrazones [5a–j]
To a solution of 4 (0.01 mol) in 10 ml ofDMF; appropriate alde-
hydes a–j (0.012 mol) and 3–4 drops of glacial acetic acid were
added.The reactionmixturewas reﬂuxed for 5–6 h.The reaction
mixture was cooled and poured onto crushed ice. The reaction
was monitored by TLC on silica gel using toluene:ethyl acetate
(3:1). The separated solid was isolated, washed with water and
recrystallized from ethanol to give 5a–j.
2.2.3. 2-[N-(6-methoxybenzothiazolyl)amino] pyridine-3-
(phenyl) hydrazone [5a]
M.p. 119–121 C, yield, 55%; IR (KBr) m cm1: 3418 (NH
str.), 1645 (CONH, amide-I), 1550 (amide-II), 1224 (amide-
III), 1610 (C‚N str., Schiff base), 1463 (C–N, C–C ring
str.), 1342 (C–N str.), 1038, 1182 (OCH3, sym., asym.).
1H
NMR (DMSO-d6) d (ppm): 9.35 (s, 1H, NH), 8.85 (s, 1H,
CONH), 6.84–8.57 (m, 11H, aromatic and pyridine), 5.83 (s,
1H, N‚CH), 3.85 (s, 3H, OCH3).
13C NMR (100 MHz,
DMSO-d6) d (ppm): 162.1 (C7), 143.3 (C8), 112.6–161.5 (C2–
C6), 104.3–172.5 (C9–C15), 51.9 (C16), 125.3–136.5 (C17–C22).
Anal. Calc. for C21H17O2N5S: C, 62.51; H, 4.25; N, 17.37.
Found: C, 62.46; H, 4.15; N, 17.30%.
2.2.4. 2-[N-(6-methoxybenzothiazolyl)amino] pyridine-3-(2-
chlorophenyl) hydrazone [5b]
M.p. 191–192 C, yield, 58%; IR (KBr) m cm1: 3421 (NH
str.), 1648 (CONH, amide-I), 1550 (amide-II), 1222 (amide-
III), 1614 (C‚N str., Schiff base), 1469 (C–N, C–C ring
str.), 1340 (C–N str.), 1036, 1181 (OCH3, sym., asym.), 760
(C–Cl). 1H NMR (DMSO-d6) d (ppm): 9.36 (s, 1H, NH),
8.87 (s, 1H, CONH), 6.81–8.56 (m, 10H, aromatic and pyri-
dine), 5.81 (s, 1H, N‚CH), 3.86 (s, 3H, OCH3).
13C NMR
(100 MHz, DMSO-d6) d (ppm): 162.3 (C7), 143.5 (C8),
112.1–161.7 (C2–C6), 104.7–172.8 (C9–C15), 51.7 (C16), 126.0–
137.1 (C17–C22). Anal. Calc. for C21H16O2N5SCl: C, 57.66;
H, 3.69; N, 16.02. Found: C, 57.58; H, 3.60; N, 15.95%.
2.2.5. 2-[N-(6-methoxybenzothiazolyl)amino] pyridine-3-(4-
chlorophenyl) hydrazone [5c]
M.p. 101–104 C, yield, 48%; IR (KBr) m cm1: 3419 (NH
str.), 1642 (CONH, amide-I), 1552 (amide-II), 1223 (amide-
III), 1609 (C‚N str., Schiff base), 1461 (C–N, C–C ring
str.), 1339 (C–N str.), 1037, 1180 (OCH3, sym., asym.), 758
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(s, 1H, CONH), 6.79–8.53 (m, 10H, aromatic and pyridine),
5.82 (s, 1H, N‚CH), 3.84 (s, 3H, OCH3).
13C NMR
(100 MHz, DMSO-d6) d (ppm): 162.5 (C7), 143.9 (C8),
112.2–161.6 (C2–C6), 104.7–172.6 (C9–C15), 52.2 (C16), 128.3–
138.9 (C17–C22). Anal. Calc. for C21H16O2N5SCl: C, 57.66;
H, 3.69; N, 16.02. Found: C, 57.60; H, 3.61; N, 15.98%.
2.2.6. 2-[N-(6-methoxybenzothiazolyl)amino] pyridine-3-(2-
nitrophenyl) hydrazone [5d]
M.p. 175–176 C, yield, 49%; IR (KBr) m cm1: 3422 (NH
str.), 1640 (CONH, amide-I), 1551 (amide-II), 1221 (amide-
III), 1611 (C‚N str., Schiff base), 1464 (C–N, C–C ring
str.), 1339 (C–N str.), 1036, 1180 (OCH3, sym., asym.), 1370,
1512 (NO2, sym., asym.).
1H NMR (DMSO-d6) d (ppm):
9.37 (s, 1H, NH), 8.82 (s, 1H, CONH), 6.82–8.56 (m, 10H, aro-
matic and pyridine), 5.81 (s, 1H, N‚CH), 3.83 (s, 3H, OCH3).
13C NMR (100 MHz, DMSO-d6) d (ppm): 162.0 (C7), 143.4
(C8), 112.7–161.8 (C2–C6), 104.2–172.3 (C9–C15), 52.1 (C16),
122.9–148.5 (C17–C22). Anal. Calc. for C21H16O4N6S: C,
56.24; H, 3.60; N, 18.75. Found: C, 56.18; H, 3.50; N, 18.65%.
2.2.7. 2-[N-(6-methoxybenzothiazolyl)amino] pyridine-3-(3-
nitrophenyl) hydrazone [5e]
M.p. 121–123 C, yield, 54%; IR (KBr) m cm1: 3421 (NH
str.), 1641 (CONH, amide-I), 1552 (amide-II), 1223 (amide-
III), 1611 (C‚N str., Schiff base), 1471 (C–N, C–C ring
str.), 1338 (C–N str.), 1037, 1178 (OCH3, sym., asym.), 1369,
1511 (NO2, sym., asym.).
1H NMR (DMSO-d6) d (ppm):
9.37 (s, 1H, NH), 8.89 (s, 1H, CONH), 6.83–8.56 (m, 10H, aro-
matic and pyridine), 5.87 (s, 1H, N‚CH), 3.87 (s, 3H, OCH3).
13C NMR (100 MHz, DMSO-d6) d (ppm): 162.8 (C7), 143.1
(C8), 112.6–161.7 (C2–C6), 104.1–171.9 (C9–C15), 51.6 (C16),
121.3–149.1 (C17–C22). Anal. Calc. for C21H16O4N6S: C,
56.24; H, 3.60; N, 18.75. Found: C, 56.19; H, 3.52; N, 18.68%.
2.2.8. 2-[N-(6-methoxybenzothiazolyl)amino] pyridine-3-(4-
hydroxyphenyl) hydrazone [5f]
M.p. 173–174 C, yield, 59%; IR (KBr) m cm1: 3422 (O–H),
3202 (NH str.), 1644 (CONH, amide-I), 1548 (amide-II),
1223 (amide-III), 1614 (C‚N str., Schiff base), 1466 (C–N,
C–C ring str.), 1341 (C–N str.), 1036, 1180 (OCH3, sym.,
asym.). 1H NMR (DMSO-d6) d (ppm): 9.31 (s, 1H, NH),
8.79 (s, 1H, CONH), 6.82–8.54 (m, 10H, aromatic and pyri-
dine), 5.85 (s, 1H, N‚CH), 3.86 (s, 3H, OCH3).
13C NMR
(100 MHz, DMSO-d6) d(ppm): 163.3 (C7), 143.2 (C8), 112.4–
161.6 (C2–C6), 104.5–172.7 (C9–C15), 51.4 (C16), 115.3–161.5
(C17–C22). Anal. Calc. for C21H17O3N5S: C, 60.13; H, 4.09;
N, 16.71. Found: C, 60.05; H, 4.00; N, 16.65%.
2.2.9. 2-[N-(6-methoxybenzothiazolyl)amino] pyridine-3-(4-
methoxyphenyl) hydrazone [5g]
M.p. 165–167 C, yield, 57%; IR (KBr) m cm1: 3421 (NH
str.), 1643 (CONH, amide-I), 1545 (amide-II), 1228 (amide-
III), 1615 (C‚N str., Schiff base), 1469 (C–N, C–C ring
str.), 1340 (C–N str.), 1039, 1179 (OCH3, sym., asym.).
1H
NMR (DMSO-d6) d (ppm): 9.34 (s, 1H, NH), 8.86 (s, 1H,
CONH), 6.86–8.58 (m, 10H, aromatic and pyridine), 5.81 (s,
1H, N‚CH), 3.88 (s, 3H, OCH3).
13C NMR (100 MHz,
DMSO-d6) d (ppm): 163.1 (C7), 142.9 (C8), 113.1–160.8 (C2–
C6), 104.7–172.6 (C9–C15), 51.3 (C16), 114.1–163.5 (C17–C22).Anal. Calc. for C22H19O3N5S: C, 60.95; H, 4.42; N, 16.17.
Found: C, 60.85; H, 4.35; N, 16.10%.
2.2.10. 2-[N-(6-methoxybenzothiazolyl) amino] pyridine-3-(3-
methoxy-4-hydroxyphenyl) hydrazone [5h]
M.p. 127–128 C, yield, 63%; IR (KBr) m cm1: 3424 (O–H),
3207 (NH str.), 1645 (CONH, amide-I), 1551 (amide-II),
1223 (amide-III), 1616 (C‚N str., Schiff base), 1464 (C–N,
C–C ring str.), 1342 (C–N str.), 1037, 1181 (OCH3, sym.,
asym.). 1H NMR (DMSO-d6) d (ppm): 9.36 (s, 1H, NH),
8.87 (s, 1H, CONH), 6.83–8.58 (m, 9H, aromatic and pyri-
dine), 5.80 (s, 1H, N‚CH), 3.86 (s, 3H, OCH3).
13C NMR
(100 MHz, DMSO-d6) d (ppm): 163.5 (C7), 143.1 (C8),
112.7–161.2 (C2–C6), 104.8–172.9 (C9–C15), 51.4 (C16), 115.3–
151.5 (C17–C22). Anal. Calc. for C22H19O4N5S: C, 58.78; H,
4.26; N, 15.59. Found: C, 58.70; H, 4.18; N, 15.50%.
2.2.11. 2-[N-(6-methoxybenzothiazolyl) amino] pyridine-3-(3-
methoxy-4-hydroxy-5nitrophenyl) hydrazone [5i]
M.p. 156–158 C, yield, 65%; IR (KBr) m cm1: 3421 (O–H),
3203 (NH str.), 1647 (CONH, amide-I), 1552 (amide-II), 1225
(amide-III), 1613 (C‚N str., Schiff base), 1470 (C–N, C–C ring
str.), 1338 (C–N str.), 1037, 1181 (OCH3, sym., asym.), 1368,
1510 (NO2, sym., asym.).
1H NMR (DMSO-d6) d (ppm): 9.37
(s, 1H, NH), 8.87 (s, 1H, CONH), 6.82–8.56 (m, 8H, aromatic
and pyridine), 5.84 (s, 1H, N‚CH), 3.85 (s, 3H, OCH3).
13C
NMR (100 MHz, DMSO-d6) d (ppm): 163.1 (C7), 143.3 (C8),
112.6–161.5 (C2–C6), 104.3–172.5 (C9–C15), 51.9 (C16), 115.3–
156.5 (C17–C22). Anal. Calc. for C22H18O6N6S: C, 53.43; H,
3.67; N, 17.00. Found: C, 53.35; H, 3.60; N, 16.95%.
2.2.12. 2-[N-(6-methoxybenzothiazolyl)amino] pyridine-3-
(furyl) hydrazone [5j]
M.p. 142–144 C, yield, 55%; IR (KBr) m cm1: 3419 (NH
str.), 1641 (CONH, amide-I), 1553 (amide-II), 1223 (amide-
III), 1614 (C‚N str., Schiff base), 1472 (C–N, C–C ring
str.), 1339 (C–N str.), 1035, 1181 (OCH3, sym., asym.).
1H
NMR (DMSO-d6) d (ppm): 9.38 (s, 1H, NH), 8.86 (s, 1H,
CONH), 6.86–8.52 (m, 9H, aromatic and pyridine), 5.81 (s,
1H, N‚CH), 3.86 (s, 3H, OCH3).
13C NMR (100 MHz,
DMSO-d6) d (ppm): 162.7 (C7), 134.3 (C8), 112.6–161.5 (C2–
C6), 104.3–172.5 (C9–C15), 51.9 (C16), 125.3–136.5 (C17–C20).
Anal. Calc. for C19H15O3N5S: C, 58.00; H, 3.85; N, 17.81.
Found: C, 57.92; H, 3.75; N, 17.75%.
2.2.13. General method for preparation of 4-thiazolidinones
[6a–j]
A mixture of appropriate hydrazones 5a–j (0.01 mol), thiogly-
colic acid (0.015 mol) and a pinch of anhydrous ZnCl2 in dry
1,4-dioxane was reﬂuxed for 12–14 h. The reaction was moni-
tored by TLC on silica gel using toluene:ethyl acetate (3:1).
The reaction mixture was cooled and neutralized with 10% so-
dium bicarbonate solution. The separated solid was ﬁltered,
washed with water and recrystallized from ethanol to give 6a–j.
2.2.14. 2-[N-(6-methoxybenzothiazolyl)amino] pyridine-3-(2-
phenyl) carboxamido-1,3-thiazolidin-4-one [6a]
M.p. 210–212 C, yield, 57%; IR (KBr) m cm1: 3416 (NH
str.), 1712 (amidic lactam), 1646 (amide-I), 1556 (amide-II),
1229 (amide-III), 1469 (C–N, C–C ring str.), 1341 (C–N str.),
1037, 1181 (OCH3, sym., asym.).
1H NMR (400 MHz,
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6.74–8.72 (m, 11H, aromatic and pyridine), 6.11 (s, 1H, CH
of 4-thiazolidinone ring), 3.64 (s, 2H, SCH2CO of 4-thiazolid-
inone ring), 3.88 (s, 3H, OCH3).
13C NMR (100 MHz, DMSO-
d6) d (ppm): 163.1 (C7), 169.3 (C8), 35.9 (C9), 57.7 (C10), 111.6–
163.5 (C2–C6), 104.3–173.9 (C11–C17), 54.9 (C18), 125.3–139.5
(C19–C24). Anal. Calc. for C23H19O3N5S2: C, 57.85; H, 4.01;
N, 14.68. Found: C, 57.80; H, 3.96; N, 14.60%.
2.2.15. 2-[N-(6-methoxybenzothiazolyl)amino] pyridine-3-[2-
(2-chlorophenyl)] carboxamido-1,3-thiazolidin-4-one [6b]
M.p. 216–217 C, yield, 49%; IR (KBr) m cm1: 3417 (NH str.),
1710 (amidic lactam), 1644 (amide-I), 1556 (amide-II), 1227
(amide-III), 1466 (C–N, C–C ring str.), 1340 (C–N str.), 758
(C–Cl), 1037, 1181 (OCH3, sym., asym.).
1H NMR (400 MHz,
DMSO-d6) d (ppm): 9.34 (s, 1H, NH), 8.89 (s, 1H, CONH),
6.76–8.71 (m, 10H, aromatic and pyridine), 6.10 (s, 1H, CH of
4-thiazolidinone ring), 3.62 (s, 2H, SCH2COof 4-thiazolidinone
ring), 3.85 (s, 3H, OCH3).
13C NMR (100 MHz, DMSO-d6) d
(ppm): 163.4 (C7), 169.2 (C8), 35.7 (C9), 57.8 (C10), 111.2–
163.7 (C2–C6), 104.1–173.6 (C11–C17), 54.7 (C18), 101.3–136.5
(C19–C24). Anal. Calc. for C23H18O3N5S2Cl: C, 54.01; H, 3.55;
N, 13.70. Found: C, 53.95; H, 3.48; N, 13.62%.
2.2.16. 2-[N-(6-methoxybenzothiazolyl)amino] pyridine-3-[2-
(4-chlorophenyl)] carboxamido-1,3-thiazolidin-4-one [6c]
M.p. 198–200 C, yield, 48%; IR (KBr) m cm1: 3416 (NH str.),
1712 (amidic lactam), 1646 (amide-I), 1562 (amide-II), 1229
(amide-III), 1464 (C–N, C–C ring str.), 1340 (C–N str.), 757
(C–Cl), 1036, 1178 (OCH3, sym., asym.).
1H NMR (400 MHz,
DMSO-d6) d (ppm): 9.31 (s, 1H, NH), 8.93 (s, 1H, CONH),
6.71–8.76 (m, 10H, aromatic and pyridine), 6.15 (s, 1H, CH of
4-thiazolidinone ring), 3.59 (s, 2H, SCH2COof 4-thiazolidinone
ring), 3.83 (s, 3H, OCH3).
13C NMR (100 MHz, DMSO-d6) d
(ppm): 163.2 (C7), 169.7 (C8), 35.4 (C9), 57.6 (C10), 111.4–
163.8 (C2–C6), 104.7–173.5 (C11–C17), 54.4 (C18), 127.3–139.3
(C19–C24). Anal. Calc. for C23H18O3N5S2Cl: C, 54.01; H, 3.55;
N, 13.70. Found: C, 53.96; H, 3.49; N, 13.65%.
2.2.17. 2-[N-(6-methoxybenzothiazolyl)amino] pyridine -3-[2-
(2-nitrophenyl)] carboxamido-1,3-thiazolidin-4-one [6d]
M.p. 227–229 C, yield, 59%; IR (KBr) m cm1: 3414 (NH
str.), 1708 (amidic lactam), 1641 (amide-I), 1558 (amide-II),
1225 (amide-III), 1467 (C–N, C–C ring str.), 1338 (C–N str.),
1371, 1514 (NO2, sym., asym.), 1036, 1180 (OCH3, sym.,
asym.). 1H NMR (400 MHz, DMSO-d6) d (ppm): 9.35 (s,
1H, NH), 8.92 (s, 1H, CONH), 6.69–8.70 (m, 10H, aromatic
and pyridine), 6.14 (s, 1H, CH of 4-thiazolidinone ring), 3.58
(s, 2H, SCH2CO of 4-thiazolidinone ring), 3.84 (s, 3H,
OCH3).
13C NMR (100 MHz, DMSO-d6) d (ppm): 163.3
(C7), 169.4 (C8), 35.6 (C9), 57.1 (C10), 111.3–163.4 (C2–C6),
104.5–173.7 (C11–C17), 54.6 (C18), 124.3–149.9 (C19–C24).
Anal. Calc. for C23H18O5N6S2: C, 52.87; H, 3.47; N, 16.09.
Found: C, 52.80; H, 3.40; N, 16.00%.
2.2.18. 2-[N-(6-methoxybenzothiazolyl)amino] pyridine-3-[2-
(3-nitrophenyl)] carboxamido-1,3-thiazolidin-4-one [6e]
M.p. 236–238 C, yield, 62%; IR (KBr) m cm1: 3416 (NH
str.), 1711 (amidic lactam), 1648 (amide-I), 1560 (amide-II),
1227 (amide-III), 1466 (C–N, C–C ring str.), 1343 (C–N str.),
1365, 1510 (NO2, sym., asym.), 1038, 1182 (OCH3, sym.,asym.). 1H NMR (400 MHz, DMSO-d6) d (ppm): 9.35 (s,
1H, NH), 8.92 (s, 1H, CONH), 6.72–8.76 (m, 10H, aromatic
and pyridine), 6.15 (s, 1H, CH of 4-thiazolidinone ring), 3.59
(s, 2H, SCH2CO of 4-thiazolidinone ring), 3.84 (s, 3H,
OCH3).
13C NMR (100 MHz, DMSO-d6) d (ppm): 163.1
(C7), 169.2 (C8), 35.7 (C9), 57.1 (C10), 111.1–163.2 (C2–C6),
104.3–173.7 (C11–C17), 54.4 (C18), 123.1–149.1 (C19–C24).
Anal. Calc. for C23H18O5N6S2: C, 52.87; H, 3.47; N, 16.09.
Found: C, 52.82; H, 3.41; N, 16.03%.
2.2.19. 2-[N-(6-methoxybenzothiazolyl)amino] pyridine-3-[2-
(4-hydroxyphenyl)] carboxamido-1,3-thiazolidin-4-one [6f]
M.p. 186–189 C, yield, 67%; IR (KBr) m cm1: 3414 (O–H str.),
3206 (NH str.), 1714 (amidic lactam), 1646 (amide-I), 1559
(amide-II), 1228 (amide-III), 1462 (C–N, C–C ring str.), 1341
(C–N str.), 1037, 1181 (OCH3, sym., asym.).
1H NMR
(400 MHz, DMSO-d6) d (ppm): 9.32 (s, 1H, NH), 8.91 (s, 1H,
CONH), 6.74–8.72 (m, 10H, aromatic and pyridine), 6.11 (s,
1H,CHof 4-thiazolidinone ring), 3.64 (s, 2H, SCH2COof 4-thia-
zolidinone ring), 3.85 (s, 3H, OCH3).
13C NMR (100 MHz,
DMSO-d6) d (ppm): 163.7 (C7), 169.4 (C8), 35.5 (C9), 57.3 (C10),
111.4–163.1 (C2–C6), 104.8–173.1 (C11–C17), 54.2 (C18), 115.3–
158.7 (C19–C24). Anal. Calc. for C23H19O4N5S2: C, 55.97; H,
3.88; N, 14.20. Found: C, 55.90; H, 3.80; N, 14.14%.
2.2.20. 2-[N-(6-methoxybenzothiazolyl)amino] pyridine-3-[2-
(4-methoxyphenyl)] carboxamido-1,3-thiazolidin-4-one [6g]
M.p. 256–257 C, yield, 54%; IR (KBr) m cm1: 3416 (NH
str.), 1709 (amidic lactam), 1649 (amide-I), 1554 (amide-II),
1229 (amide-III), 1468 (C–N, C–C ring str.), 1346 (C–N str.),
1039, 1186 (OCH3 str., sym., asym.).
1H NMR (400 MHz,
DMSO-d6) d (ppm): 9.34 (s, 1H, NH), 8.91 (s, 1H, CONH),
6.73–8.74 (m, 10H, aromatic and pyridine), 6.11 (s, 1H, CH
of 4-thiazolidinone ring), 3.58 (s, 2H, SCH2CO of 4-thiazolid-
inone ring), 3.83 (s, 3H, OCH3).
13C NMR (100 MHz, DMSO-
d6) d (ppm): 163.6 (C7), 169.4 (C8), 35.5 (C9), 57.6 (C10), 111.9–
163.3 (C2–C6), 104.1–173.8 (C11–C17), 54.1 (C18), 114.3–159.5
(C19–C24). Anal. Calc. for C24H21O4N5S2: C, 56.79; H, 4.17;
N, 13.81. Found: C, 56.70; H, 4.10; N, 13.76%.
2.2.21. 2-[N-(6-methoxybenzothiazolyl)amino] pyridine-3-[2-
(3-methoxy-4-hydroxy-phenyl)] carboxamido-1,3-thiazolidin-
4-one [6h]
M.p. 239–241 C,yield, 56%; IR (KBr) m cm1: 3410 (O–H), 3210
(NH str.), 1711 (amidic lactam), 1647 (amide-I), 1558 (amide-II),
1225 (amide-III), 1469 (C–N, C–C ring str.), 1344 (C–N str.),
1032, 1192 (OCH3 str., sym., asym.).
1H NMR (400 MHz,
DMSO-d6) d (ppm): 9.34 (s, 1H, NH), 8.95 (s, 1H, CONH),
6.69–8.73 (m, 9H, aromatic and pyridine), 6.09 (s, 1H, CH of 4-
thiazolidinone ring), 3.61 (s, 2H, SCH2CO of 4-thiazolidinone
ring), 3.87 (s, 3H, OCH3).
13C NMR (100 MHz, DMSO-d6) d
(ppm): 163.2 (C7), 169.3 (C8), 35.4 (C9), 57.6 (C10), 111.1–163.7
(C2–C6), 104.5–173.2 (C11–C17), 54.8 (C18), 115.3–151.7 (C19–
C24). Anal. Calc. for C24H21O5N5S2: C, 55.06; H, 4.05; N, 13.38.
Found: C, 55.00; H, 3.95; N, 13.30%.
2.2.22. 2-[N-(6-methoxybenzothiazolyl)amino] pyridine-3-[2-
(3-methoxy-4-hydroxy-5-nitrophenyl)] carboxa-mido-1,3-
thiazolidin-4-one [6i]
M.p. 217–220 C, yield, 62%; IR (KBr) m cm1: 3416 (O–H
str.), 3212 (NH str.), 1711 (amidic lactam), 1646 (amide-I),
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Figure 2 4-Thiazolidinones 6a–j.
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1342 (C–N str.), 1369, 1516 (NO2, sym., asym.), 1036, 1194
(OCH3 str., sym., asym.).
1H NMR (400 MHz, DMSO-d6) d
(ppm): 9.37 (s, 1H, NH), 8.94 (s, 1H, CONH), 6.71–8.75 (m,
8H, aromatic and pyridine), 6.10 (s, 1H, CH of 4-thiazolidi-
none ring), 3.63 (s, 2H, SCH2CO of 4-thiazolidinone ring),
3.82 (s, 3H, OCH3).
13C NMR (100 MHz, DMSO-d6) d
(ppm): 163.5 (C7), 169.7 (C8), 35.7 (C9), 57.3 (C10), 111.7–
163.8 (C2–C6), 104.1–173.5 (C11–C17), 54.4 (C18), 118.1–153.1
(C19–C24). Anal. Calc. for C24H20O7N6S2: C, 50.70; H, 3.55;
N, 14.79. Found: C, 50.65; H, 3.45; N, 14.70%.
2.2.23. 2-[N-(6-methoxybenzothiazolyl)amino] pyridine-3-(2-
furyl) carboxamido-1,3-thiazolidin-4-one [6j]
M.p. 204–206 C, yield, 51%; IR (KBr) m cm1: 3412 (NH
str.), 1710 (amidic lactam), 1649 (amide-I), 1558 (amide-II),
1225 (amide-III), 1467 (C–N, C–C ring str.), 1345 (C–N str.),
1037, 1186 (OCH3, sym., asym.).
1H NMR (400 MHz,
DMSO-d6) d (ppm): 9.34 (s, 1H, NH), 8.94 (s, 1H, CONH),
6.72–8.71 (m, 9H, aromatic and pyridine), 6.13 (s, 1H, CH
of 4-thiazolidinone ring), 3.63 (s, 2H, SCH2CO of 4-thiazolid-
inone ring), 3.85 (s, 3H, OCH3).
13C NMR (100 MHz, DMSO-
d6) d (ppm): 163.8 (C7), 169.1 (C8), 35.0 (C9), 57.1 (C10), 111.2–
163.1 (C2–C6), 104.4–173.1 (C11–C17), 54.8 (C18), 104.7–151.5
(C19–C24). Anal. Calc. for C21H17O4N5S2: C, 53.95; H, 3.67;
N, 14.99. Found: C, 53.88; H, 3.60; N, 14.90% (Figs. 1 and 2).
2.3. Antimicrobial screening
All MTCC cultures were collected from Institute of Microbial
Technology, Chandigarh and tested against known drugs
ampicillin and greseofulvin. Mueller–Hinton broth was used
as nutrient medium to grow and dilute the drug suspension
for the test. Inoculum size for test strain was adjusted to 108
CFU (Colony Forming Unit) per milliliter by comparing the
turbidity. DMSO was used as diluents to get desired concen-
tration of drugs to test upon standard bacterial strains. Serial
dilutions were prepared in primary and secondary screening.
The control tube containing no antibiotic was immediatelyS
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Figure 1 Hydrazones 5a–j.subcultured (before inoculation) by spreading a loopful evenly
over a quarter of plate of medium suitable for the growth of
the test organism and put for incubation at 37 C overnight.
The tubes were then incubated overnight. The MIC of the con-
trol organism was read to check the accuracy of the drug con-
centrations. The lowest concentration inhibiting growth of the
organism was recorded as the MIC. All the tubes not showing
visible growth (in the same manner as control tube described
above) was subcultured and incubated overnight at 37 C.
The amount of growth from the control tube before incubation
(which represents the original inoculum) was compared. Sub-
cultures might show: similar number of colonies indicating
bacteriostatic; a reduced number of colonies indicating a par-
tial or slow bactericidal activity and no growth if the whole
inoculum has been killed. The test included a second set of
the same dilutions inoculated with an organism of known sen-
sitivity. Each synthesized drug was diluted obtaining 2000 lg/
ml concentration, as a stock solution. In primary screening
500, 250 and 125 lg/ml concentrations of the synthesized
drugs were taken. The active synthesized drugs found in this
primary screening were further tested in a second set of dilu-
tion against all microorganisms. The drugs found active in
primary screening were similarly diluted to obtain 100, 50,
25, 12.5, 6.250, 3.125 and 1.5625 lg/ml concentrations. The
highest dilution showing at least 99% inhibition is taken as
MIC (Scheme 1).
3. Results and discussion
3.1. Chemistry
2-Chloro pyridine-3-carboxylic acid 1 and 2-amino-6-methoxy
benzothiazole 2 in presence of anhydrous K2CO3 and catalytic
amount of Cu-bronze in DMF solvent were heated (Ullamann
Condensation) to form 2-[N-(6-methoxybenzothiazolyl)amino]
pyridine-3-carboxylic acid 3 which on further heating in
thionyl chloride and subsequent reaction with hydrazine
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d : R = 2-NO2 i : R = 3-OCH3-4-OH-5-NO2
e : R = 3-NO2 j : R = C4H3O (Furyl) 
Scheme 1 Synthetic protocol of 5a–j and 6a–j. 5j and 6j contains furyl nucleus as illustrated in Figs. 1 and 2. Synthesis of the compounds
4, 5a–j and 6a–j. Reagents and conditions: (A) (i) SOCl2 and (ii) hydrazine hydrate, chloroform, triethylamine; (B) aromatic aldehydes,
DMF, 1–2 drop glacial acetic acid, 5–6 h (C) thioglycolic acid, anhydrous ZnCl2, 1,4-dioxane, 12–14 h.
134 N.B. Patel, F.M. Shaikhhydrate in chloroform formed acid hydrazide 4. After condens-
ing, 4 with aromatic aldehydes a–j in DMF solvent, Schiff
bases 5a–j were obtained. Finally, 4-thiazolidinones 6a–j were
prepared by reﬂuxing the related hydrazide–hydrazones 5a–j
and thioglycolic acid in dry 1,4-dioxane for 12–14 h using a
Dean–Stark apparatus.
The structures of synthesized compounds 5a–j were con-
ﬁrmed by elemental analyses and IR spectra (cm1) absorption
bands at 3419 (NH), 1646 (amide-I), 1612 (–N‚CH–), 1556
(amide-II), 1340 (C–N), 1225 (amide-III), 1036, 1186 (C–O–
C). Some additional peaks appear due to substitution in aro-
matic ring showing absorption band at 3410 (O–H), 1370,
1512 (–NO2 sym., asym.), 758 (CCl). In
1H NMR spectra com-
mon signals that appear are: dH (ppm): a singlet at d 8.85 cor-
responds to >CONH, a singlet at d 5.83 for –N‚CH–, a
multiplet at d 6.84–8.57corresponds to aromatic proton. A sin-
glet at d 3.85 for –OCH3, and due to the substitution on aro-
matic ring, a singlet appeared at d 5.15 corresponding to –OH.
The structure of compounds 6a–j were supported by ele-
mental analyses and IR spectra as observed in 5a–j with disap-
pearance of 1612 cm1 for –N‚CH– band with 1710 cm1 for
>C‚O of thiazolidinone. The 1H NMR singlet signals of cy-
clized thiazolidinone was observed at d 3.58–3.64, correspond-
ing to –CH2– in the ring, and d 6.09–6.15, corresponding to
C2–H. The other signals observed were same as 5a–j.
3.2. Antimicrobial activity
Antibacterial activity of the synthesized compounds 5a–j and
6a–j in form of minimum inhibitory concentrations (MICs)
was evaluated against various pathogenic bacterial strains
(Gram-negative and Gram-positive) viz., Staphylococcus aur-eusMTCC 96, Streptococcus pyogenesMTCC 442, Escherichia
coli MTCC 443, Pseudomonas aeruginosa MTCC 741. Anti-
fungal activity of these compounds 5a–j and 6a–j was evalu-
ated against fungal strains viz. Candida albicans MTCC 227,
Aspergillus niger MTCC 282 and Aspergillus clavatus MTCC
1323. The antimicrobial activities were carried out by broth
micro dilution method as described by Rattan (2005). Mini-
mum inhibitory concentrations (MICs) of the tested com-
pounds are shown in Table 1. Ampicillin was used as a
reference drug for antibacterial activity whereas greseofulvin
was used as a reference drug for antifungal activity.3.3. Antibacterial activity
The results of antibacterial screening of the synthesized com-
pounds are presented in Table 1. Modest antibacterial activity
is observed with most of the tested compounds.
Some of synthesized compounds showed good to moderate
activity with MIC value in the range of 62.5–100 lg/ml. Partic-
ularly, compound 5h, 5j, 6b and 6d showed good activity (MIC
value 100 lg/ml) against E. coli and 6h showed signiﬁcant
activity (MIC value 62.5 and 100 lg/ml, respectively) against
E. coli and P. aeruginosa, respectively. Moreover, 5a, 5b, 5d,
5e, 5g, 5i, 5j, 6a, 6b, 6c, 6f, 6g, 6h and 6j displayed comparable
activity (MIC value 100–250 lg/ml) against S. aureus relative
to the reference drug ampicillin.3.4. Antifungal activity
The results of antifungal screening of the synthesized com-
pounds are presented in Table 1. Starting material 1, 2, 3
Table 1 Biological proﬁle of compounds 5a–j and 6a–j.
Compounds Minimal inhibitory concentration (MIC) lg/ml
Tested bacteria Tested fungi
Gram-negative Gram-positive
E. coli P. aeruginosa S. aureus S. pyogenes C. albicans A. niger A. clavatus
1 150 150 200 250 250 500 500
2 150 250 250 500 250 500 500
3 125 500 200 250 250 500 500
4 200 500 500 500 500 500 500
5a 150 200 250 250 500 500 500
5b 500 500 200 200 1000 >1000 >1000
5c 250 250 500 500 100 500 500
5d 200 250 150 200 500 500 1000
5e 250 500 150 150 500 1000 1000
5f 500 500 500 500 500 500 1000
5g 150 200 200 200 100 500 500
5h 100 500 500 500 200 500 500
5i 500 500 250 250 500 >1000 >1000
5j 100 200 150 200 1000 1000 1000
6a 500 1000 250 250 500 1000 1000
6b 100 150 100 150 500 1000 1000
6c 500 250 200 200 1000 >1000 >1000
6d 100 200 250 250 1000 1000 1000
6e 250 250 500 500 500 500 500
6f 200 200 250 500 500 1000 1000
6g 500 500 200 200 500 500 500
6h 62.5 100 250 250 1000 1000 1000
6i 200 500 500 500 1000 1000 1000
6j 200 200 250 250 500 500 500
Ampicillin 100 100 250 100 – – –
Greseofulvin – – – – 500 100 100
Synthesis and antimicrobial activity of new 4-thiazolidinone derivatives 135and 4 showed better activity against C. albicans (MIC value
250–500 lg/ml) compared with standard drug greseofulvin.
Some of the synthesized compounds 5a–j and 6a–j showed
good to moderate activity with MIC value in the range of 100–
500 lg/ml. Particularly, compounds 5c, 5g and 5h, 5a, 5d, 5e,
5f, 5i, 6a, 6b, 6e, 6f, 6g and 6j showed comparable activity
against C. albicans compared to the reference drug greseoful-
vin. All compounds from Schiff base and 4-thiazolidinone ser-
ies showed weak to no activity against A. niger and A. clavatus.
4. Conclusion
Novel Schiff bases and 4-thiazolidinones of pyridine and ben-
zothiazole derivatives were synthesized; starting from building
blocks 1 and 2 and were studied for their antimicrobial
activity. Overall observation from the results of the antimicro-
bial activity of the synthesized compounds revealed that
compounds containing –Cl, –NO2 group and furan nucleus
are more active than the remaining compounds.
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